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Abstract
The purpose of this work is to define safe irradiation protocols in microbeam
radiation therapy. The intense synchrotron-generated x-ray beam used for the
treatment is collimated and delivered in an array of 50 μm-sized rectangular
fields with a centre-to-centre distance between microplanes of 400 μm. The
absorbed doses received by the tumour and the healthy tissues in a human
head phantom have been assessed by means of Monte Carlo simulations. The
identification of safe dose limits is carried out by evaluating the maximum peak
and valley doses achievable in the tumour while keeping the valley doses in the
healthy tissues under tolerances. As the skull receives a significant fraction of
the dose, the dose limits are referred to this tissue. Dose distributions with high
spatial resolution are presented for various tumour positions, skull thicknesses
and interbeam separations. Considering a unidirectional irradiation (field size
of 2×2 cm2) and a centrally located tumour, the largest peak and valley doses
achievable in the tumour are 55 Gy and 2.6 Gy, respectively. The corresponding
maximum valley doses received by the skin, bone and healthy brain are 4 Gy,
14 Gy and 7 Gy (doses in one fraction), respectively, i.e. within tolerances (5%
probability of complication within 5 years).
(Some figures in this article are in colour only in the electronic version)
1. Introduction
Gliomas are extremely radioresistant tumours. The high absorbed doses needed to ablate
gliomas are limited by the high morbidity of the surrounding healthy tissue, especially
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in children (Kagan et al 1976). The average lifespan for these patients is less than
1 year, and generally no patient survives 5 years after treatment (Behin et al 2003). High-
grade gliomas are still of poor prognostic value despite the development of many innovative
therapies. Stereotactic radiosurgery (Phillips et al 1994), intensity-modulated radiation therapy
(Cardinale et al 1998) and boron neutron capture therapy (Barth et al 2005) are some examples.
The use of radiotherapy plus concomitant and adjuvant temozolomide has allowed a significant
prolongation of survival (Stupp et al 2002, 2005, 2009). However, the outcome still remains
unsatisfactory and the management of glioblastomas is mainly palliative.
One possible way to improve the therapeutic index in radiotherapy is to employ new
techniques based on what is known as the dose–volume effect: the smaller the field size,
the higher the tolerance of the healthy tissue (Curtis 1967). Microbeam radiation therapy
(MRT) is a synchrotron radiotherapy technique that relies on this fact. Such an irradiation
can be palliative or curative while causing minimal damage to the contiguous healthy
tissue.
In MRT, the irradiation is carried out by means of an array of parallel x-ray microbeams
(from 25 to 50 μm thick), with a centre-to-centre (c-t-c) distance between microbeams of
200 or 400 μm. The x-ray energy spectrum ranges from about 50 to 500 keV, with a
mean energy around 100 keV (Siegbahn et al 2006). The microbeams are produced by a
multi-slit collimator that spatially fractionates in the horizontal direction the beam coming
from the synchrotron source (Bra¨uer-Krisch et al 2009). Targets are then vertically scanned
through the microfractionated beam to deliver microplanes of x-rays. The synchrotron
origin of the microbeams confers them two crucial features: negligible divergence (allowing
the production of sharply defined beam edges in tissue) and high flux (enabling a fast
irradiation process that prevents motion artifacts of the subject caused by cardiosynchronous
pulsation).
The MRT irradiation scheme results in dose profiles consisting of a pattern of peaks and
valleys, i.e. with high doses in the microbeam paths and low doses in the spaces between them
(Siegbahn et al 2006). The minimum dose in the central region between two microbeams is
named valley dose and the dose in the centre of the microbeam is the peak dose.
The ratio between the peak dose and the valley dose (peak-to-valley dose ratio, PVDR)
depends on the incident x-ray beam energy, the tissue composition, the beam thickness, the
c-t-c distance and the irradiation field size but it does not depend on the peak dose prescription
in the tumour. Despite being an important dosimetric parameter in this type of spatially
fractionated techniques, PVDR is a relative quantity and it is also necessary to have the
information on both peak and valley doses.
During the last two decades, several preclinical studies have shown the sparing effect
of the healthy tissue using MRT on the brain of adult rats (Slatkin et al 1995, Regnard
et al 2008), suckling rats (Laissue et al 1999), duck embryos (Dilmanian et al 2001), piglets
(Laissue et al 2001), chick-embryo chorio-amniotic membranes (Blattmann et al 2005) and
nude mice (Serduc et al 2008). In parallel, it has been proven that MRT can ablate highly
aggressive animal tumour models such as 9L brain gliomas (Laissue et al 1998, Dilmanian
et al 2002, Smilowitz et al 2006), EMT-6 carcinoma (Dilmanian et al 2003) and SCCVII
carcinoma (Miura et al 2006).
Dilmanian et al (2002) stressed the fact that MRT could cure 9L-bearing animals without
killing all tumoral cells. They suggested that MRT effects might involve mechanisms other
than a direct ionizing radiation effect on tumoral cells, like poor regenerative capacity of
tumoral vessels after radiation exposure. Additional mechanisms such as abscopal effects
may also play a role. The analysis of the results for different beam spacings from Dilmanian
et al (2002) and Regnard et al (2008) suggests that a high lesion density induced by the
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microbeams on tumour vasculature could be sufficient to treat brain tumours. Indeed, a
decrease in microbeam spacing may increase the number of vascular lesions per unit volume.
Nevertheless, the biological mechanisms following an MRT irradiation are not yet fully
understood. It has been hypothesized that the sparing effect in the healthy tissue along the
beam paths is due to a rapid biological repair of the microscopic lesions by the minimally
irradiated cells contiguous to the irradiated tissue slices (Slatkin et al 1995, Laissue et al 1998,
Dilmanian et al 2001). Dilmanian et al (2002) have shown that the sparing effect of MRT
seems to depend mostly on the valley dose. The brain-sparing effect (measured by the onset
of the appearance of white matter necrosis) vanishes only when the valley dose approaches
the tissue tolerance to broad beams. As for the PVDRs, the valley doses depend on the x-ray
beam energy spectrum, on the spacing between microbeams, on the irradiation field size but
also on the peak doses. A smaller c-t-c distance results in higher valley doses and in lower
tolerances (Dilmanian et al 2002, Regnard et al 2008).
Following the success of preclinical studies, the Biomedical Beamline ID17 of the
European Synchrotron Radiation Facility (ESRF) is planning to proceed towards clinical
trials (Laissue et al 2007, Renier et al 2008). In this context, Monte Carlo (MC) absorbed
dose calculations in realistic phantoms are needed to define irradiation protocols in MRT.
The first MC dosimetry studies in MRT were done by Slatkin et al (1992). The simulations
were performed for 25 μm thick microbeams spaced 50, 100 or 200 μm, impinging on a
16 cm long cylindrical water phantom with a diameter of 16 cm. Subsequent works considered
similar water phantoms (Stepanek et al 2000, De Felici et al 2005, Siegbahn et al 2006, Spiga
et al 2007). Company and Allen (1998) calculated also the dose distribution in a tissue/lung/
tissue phantom and Orion et al (2000) in a spherical human head phantom with a diameter
equal to 17.2 cm (0.6 cm of skull and 16 cm of brain). Prezado et al (2009b), who investigated
the dose enhancement in MRT by loading the tumour with gadolinium, have also performed
the simulations in a human head phantom inspired by the one described in the work of Harling
et al (1995).
It is important to point out that the use of realistic geometries is essential for a correct dose
assessment. For example, the valley dose in a centrally located tumour in a water phantom is
around 2.8 times higher than that of the head phantom considered in the present study. The
difference has to be mainly ascribed to the presence of the bone.
To the best of our knowledge, the only dosimetric studies carried out in MRT using a
head phantom are those of Orion et al (2000) and Prezado et al (2009b). Orion et al (2000)
used 30 μm thick microbeams, a c-t-c distance between microplanes of 100 and 200 μm and
field sizes of 3×3 and 6×6 cm2. In Prezado et al (2009b), the microbeam width, the c-t-c
distance and the irradiation field size were 50 μm, 200 μm and 2×2 cm2, respectively. The
PVDR value for a lateral irradiation of a centrally located tumour in Prezado et al (2009b) is
in agreement with our results in section 3.4 and in figure 6.
None of the parameters used in previous papers are going to be employed in the
forthcoming clinical trials at the ESRF. The chosen irradiation parameters have been fixed to
a microbeam width of 50 μm and a c-t-c distance of 400 μm in order to reach a compromise
between healthy tissue sparing and tumour eradication.
For the first time, this work presents a systematic study of the dose distribution and the
corresponding conversion of absorbed dose to normalized total dose considering biological
effects in a realistic head phantom with a high spatial resolution. The maximum dose
prescription achievable in the tumour is evaluated in different cases by adopting the criterion of
keeping the valley dose in the healthy tissue as low as possible and below tissue tolerances for
a broad beam (Dilmanian et al 2002). In this way, safe and conservative irradiation protocols
in MRT can be defined.
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2. Materials and methods
2.1. Monte Carlo simulation code: PENELOPE/penEasy
The MC code PENELOPE (Salvat et al 2006, Sempau et al 1997) has been employed.
PENELOPE simulates the coupled transport of photons, electrons and positrons in the energy
interval from 50 eV to 1 GeV, and in arbitrary material systems. PENELOPE has been widely
used in the medical physics field, see for example Sempau et al (2001), Torres et al (2004),
Sempau and Andreo (2006), Ferna´ndez-Varea et al (2007) and Sterpin et al (2008) to name
a few. In this work, penEasy (Sempau and Badal 2008), a structured general-purpose main
program for PENELOPE, has been adopted to do the calculations.
The most relevant photon interaction mechanisms in the energy range of concern in
MRT (mean energy ∼100 keV) are Compton scattering and photoelectric effect. These
interactions are simulated one by one until the photon reaches an energy lower than a user-
defined threshold (the absorption energy). Compton scattering is modelled by means of
the relativistic impulse approximation. This formalism takes into account both Doppler
broadening and binding effects of the atomic electrons. Photoelectric cross sections are
interpolated from the tabulations of the Evaluated Photon Data Library (Cullen et al 1997).
Many-body and aggregation effects are ignored and atoms are considered as independent.
Regarding electron transport, PENELOPE implements a mixed simulation algorithm in
which interactions are classified into hard and soft. They are regarded as hard when the energy
loss or the angular deflection of the transported particle is above certain user-defined cutoffs.
Hard interactions are simulated individually. Soft interactions are simulated by resorting to
multiple-scattering theories. Angular deflections are mainly caused by elastic scattering, while
inelastic collisions are the dominant energy loss mechanism. Elastic scattering cross sections
are calculated from relativistic partial-wave analysis (Salvat et al 2005). Inelastic scattering is
described by means of a schematic generalized oscillator strength model with mean excitation
energy values taken from the ICRU Report 37 (ICRU 1984).
2.2. Simulation geometry and configuration
The considered head phantom is composed of slabs of skin, bone and brain, with thicknesses
equal to 2 mm, 1 cm and 16 cm, respectively. The dimensions of the human brain are taken
from Harling et al (1995).
To obtain the dose distribution for the whole field, we have adopted the following approach.
First, we compute the dose distribution for a single microbeam in the head phantom. Next, for
each spatial location, the dose is evaluated as the sum of the contributions of each individual
microbeam to cover the desired irradiation field. In agreement with previous dosimetry works
(Boudou et al 2005, Prezado et al 2009a, Prezado et al 2009b), a field size of 2×2 cm2 is
assumed in the simulations, which corresponds to the tumour size. In the calculations, the
dose prescription is referred to as the centre of a ‘virtual’ tumour located at a certain depth.
Absorbed doses are tallied in voxels of 2 μm in the lateral direction of the microbeam,
1 mm in the vertical direction of the microbeam and 2 mm in depth. Doses were scored up to
2 cm away from the centre of the microbeam in the lateral direction (see figure 1).
There are different simulation parameters to be considered in PENELOPE. Users are
required to define an absorption energy (EABS) for each particle type (γ , e±) at which histories
are terminated and their remaining energy is locally absorbed. Charged-particle transport also
requires the setting of the following parameters: C1, which determines the average angular
deflection between two consecutive hard elastic events; C2, which defines the maximum
average fractional energy loss in a single multiple-scattering step; WCC, the cutoff energy for
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Figure 1. Scheme of the dimensions and orientation of the head phantom, as well as the voxels
used to tally the dose distribution in the simulations (not to scale).
the production of hard inelastic events; WCR, the cutoff energy for the production of hard
bremsstrahlung; and DSMAX, the maximum allowed step length.
In our simulations, EABS is set to 300 eV for all particles, to ensure that the photon mean
free path and the secondary-electron range are smaller than the minimum bin width used to
tally the dose distributions. C1 and C2 are set to 0.01, which is a very conservative value. WCC
and WCR are set equal to EABS. Finally, the value of DSMAX is chosen to be one tenth of the
different slab thicknesses.
Simulations are discontinued when the average statistical uncertainty is less than 0.5%
(2 standard deviations). This uncertainty is calculated as an average of the uncertainties of the
bins with doses above half of the maximum score.
2.3. Dose equivalence with standard fractionation schemes
Since in MRT the doses are delivered in one fraction, the expected biological effects and
tissue tolerances will depart from the values in conventional radiotherapy, where the doses are
typically delivered in 2 Gy/session (Emami et al 1991, QUANTEC 2010). To establish the
equivalence of the valley dose with the standard fractionation scheme, the normalized total
dose (NTD) has been evaluated from
NTD2.0 = nd
(
1 +
d
α/β
)(
1 +
2 Gy
α/β
)−1
, (1)
where NTD2.0 is the NTD corresponding to the standard fractionation scheme of 2 Gy/fraction,
d is the absorbed dose per fraction and n is the number of sessions. In our case, n = 1 and the
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total dose given in one MRT fraction is D = nd = d. The α/β ratio is a parameter related to
the biological response of the tissue under consideration and depends on its renewal capability.
Equation (1) is derived from the linear-quadratic (LQ) model (Flickinger and Kalend
1990) for the biological response to ionizing radiation, often employed to compare different
fractionation schemes in conventional radiotherapy because it fits the experimental cell survival
curves quite well in most cases. It is widely used to quantify the effects of radiotherapy at low
and medium doses, but it might overestimate the magnitude of cell killing for doses greater
than 10 Gy (Brenner 2008). Several attempts have been made to extend the LQ model to higher
doses per fraction, all of them leading to the inclusion of at least one additional parameter in
the formalism (Lind et al 2003, Guerrero and Li 2004). Unfortunately, the applicability is
limited because most clinical datasets are insufficient to estimate all the parameters (Joiner
and van der Kogel 2009).
There are ongoing discussions in the scientific community on the applicability of the LQ
model at high doses per fraction due to the lack of clinical data (Kirkpatrick et al 2009).
In vivo studies have suggested that the predictions of the LQ model are still acceptable for
the design of clinical trials based on doses per fraction up to 18 Gy (Brenner 2008). In vitro
investigations have shown that the cell survival followed the standard LQ model up to 15 Gy
(Garcia et al 2006). Theoretical works indicate that the LQ model remains valid up to 17 Gy
(Sachs et al 1997). As the valley dose in the present work ranges from 1 to 14 Gy in one
fraction, equation (1) can be used with reasonable confidence.
The values of α/β range from 8 to 15 Gy (Steel 2002) for tumours and early responding
tissues. The skin is a rapidly renewable tissue for which α/β = 8.8 Gy (Turesson and Thames
1989). For late responding tissues such as the brain and the bone, the values of α/β are
smaller: 2 Gy (Steel et al 2002) and 1.8 Gy (Overgaard 1988), respectively. In the latter
cases, the dose fractionation effect and the repair mechanisms between consecutive fractions
are more important than in early responding tissues, where the total absorbed dose plays a
more significant role.
The valley dose is converted into NTD2.0 to assess if it is under the tolerance level
for the well-established conventional radiotherapy limits, following the results by Dilmanian
et al (2002). According to the latest published compilations of values on human patients,
the tolerance doses (with a 5% probability of complication within 5 years from treatment,
irradiation of one-third of the whole organ volume) are 70 Gy for the skin and 50–60 Gy for
the bone (Emami et al 1991). In the case of the brain, a 5% risk of symptomatic radiation
necrosis with the standard fractionation scheme is predicted to occur at 72 Gy (Lawrence
et al 2010). For single fractionation radiosurgery, a clear correlation has been demonstrated
between the target size and the risk of adverse events. For targets smaller than 20 mm in
diameter, the maximum brain tolerance dose is higher than 24 Gy (Shaw et al 2000).
Emami et al (1991) also present the tolerance doses for 50% probability of necrosis within
5 years: >70 Gy for the skin and 65–75 Gy for the brain and the bone. The peak dose relative
to this latter case has been studied as well.
3. Results and discussion
Dose distributions for various positions of a tumour, skull thicknesses and interbeam
separations have been computed. The influence of these variables on the dose distributions
will be presented separately. Dose is reported as absorbed dose to medium.
The valley dose presented in the figures that follow is obtained in the centre of the field
since this is the location of the largest valley dose. A conservative criterion is to consider that
the absorbed dose in this valley must be lower than the tolerances in conventional radiotherapy.
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Figure 2. PVDR as a function of depth in the head phantom considering a unidirectional irradiation
with 50 μm thick microbeams and a c-t-c distance of 400 μm. The three labelled areas correspond
to skin (a), skull (b) and brain (c). Statistical uncertainty bars are at two standard deviations.
For this, we relied on the NTD2.0 to establish the equivalence between the valley dose (given
in one fraction) with the standard fractionation scheme of 2 Gy/fraction.
3.1. Dose distributions for a centrally located tumour
The most conservative tumour location to evaluate the absorbed dose in the healthy tissue is
the centre of the brain. Using a single port irradiation, the optimum ballistics will be given
by a lateral irradiation (ear-to-ear axis). With this configuration, in which the tumour centre
is at a depth of 7.2 cm with respect to the skin entrance (Harling et al 1995), the quantity of
healthy irradiated tissue is minimized.
Figure 2 shows the ratio between the peak dose and the valley dose, i.e. the PVDR, as
a function of depth. The PVDR takes values around 58 in the first 2 mm (skin), but it falls
off rapidly in the bone, reaching a value of 18 in the interface with the brain. This drastic
reduction in bone with respect to skin is due to the increase of the fluence of photons that
are Compton scattered into the valley region. These photons have a larger probability per
unit mass of undergoing a photoelectric absorption in bone since its average atomic number is
higher. This results in a higher local dose deposition. In the brain, the PVDR remains almost
constant (PVDR  25).
Figures 3 and 4 display the valley dose distribution, the peak dose distribution and the
NTD2.0 for different dose prescriptions in the centre of the tumour ranging from 40 to 65 Gy
in one fraction. The maximum valley doses are 2–5 Gy in the skin, 9–17 Gy in the bone and
4–8 Gy in the brain. The maximum values of NTD2.0 are 2–6 Gy in the skin, 30–80 Gy in the
bone and 6–18 Gy in the brain. Owing to the high effective atomic number of the bone, the
skull receives a substantial dose and it will be the limiting organ to establish the maximum
peak dose in the tumour.
The tolerance for the bone lies between 50 and 65 Gy for a 5 % probability of complications
within 5 years (Emami et al 1991). Therefore, from figure 4, the maximum tumour peak dose
prescription achievable is 55 Gy and the corresponding valley dose in the tumour is 2.6 Gy
(see figure 3 left). Considering this and the information displayed in figure 3, the maximum
peak and valley doses for all the tissues can be established. The maximum skin entrance dose
is 200 Gy and the maximum peak doses in the skull and the brain are 315 and 150 Gy. The
corresponding valley doses in the skin, skull and brain are 4, 14 and 7 Gy, respectively. In
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Figure 3. Valley dose (left) and peak dose (right) distributions for skin (a), skull (b) and brain
(c) for the indicated peak dose prescriptions in the tumour, situated at a depth of 7.2 cm. The
c-t-c distance between the 50 μm thick microbeams is 400 μm. Each curve is proportional to the
tumour dose prescription.
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Figure 4. NTD2.0 valley dose distribution for the different tissues: skin (a), skull (b) and brain (c)
for the indicated peak dose prescriptions in the tumour, situated at a depth of 7.2 cm. The c-t-c
distance between the 50 μm thick microbeams is 400 μm.
summary, if the peak dose prescription in the tumour is smaller than 55 Gy, the valley dose in
the healthy tissue will be kept under tolerances. If peak doses of 62 Gy were delivered to a
centrally located tumour, the 50 % probability of bone necrosis within 5 years in bone would
be reached (see figure 4).
Monte Carlo dosimetry for forthcoming clinical trials in x-ray MRT 4383
0
2
4
6
8
10
12
14
16
0 1 2 3 4 5 6 7 8
D
va
ll
ey
(G
y
)
depth (cm)
8 mm
9 mm
10 mm
11 mm
12 mm
0
10
20
30
40
50
60
70
0 1 2 3 4 5 6 7 8
N
T
D
2
.0
,v
a
ll
ey
(G
y
)
depth (cm)
8 mm
9 mm
10 mm
11 mm
12 mm
Figure 5. Absorbed dose (left) and NTD2.0 (right) valley dose distributions for skull thicknesses
ranging from 8 to 12 mm. The prescribed peak dose in the centre of the tumour, situated at a depth
of 7.2 cm, is 55 Gy in one fraction. The c-t-c distance between the 50 μm thick microbeams is
400 μm.
Table 1. Maximum peak dose prescription and valley dose in the tumour in one fraction keeping the
healthy tissue under tolerances (5% complication probability within 5 years) for different tumour
positions.
Depth of Maximum peak Corresponding
tumour (cm) dose (Gy) valley dose (Gy)
1.5 145 5.9
2.5 125 5.2
3.5 105 4.5
4.5 90 4.1
5.5 75 3.5
6.5 65 2.9
7.2 55 2.6
3.2. Dose distributions as a function of tumour position
The valley doses and the corresponding NTD2.0 values have been calculated for a number of
tumour positions with respect to the head surface. Table 1 lists, for several tumour locations,
the maximum peak dose that can be prescribed in the tumour to keep the corresponding valley
doses below healthy tissue tolerances. As can be seen, a deeper-seated tumour implies a lower
maximum peak dose prescription to fulfil the requested condition.
3.3. Dose distributions as a function of bone thickness
The above calculations have been done for a skull thickness of 10 mm. However, there might
be some slight variation among individuals. Figure 5 shows the valley and NTD2.0 dose
distributions for several skull thicknesses close to the value used in this work (8, 9, 11 and
12 mm). Doses were obtained for a tumour dose prescription of 55 Gy in one fraction. There
are appreciable differences in the bone but there is no variation of the deposited dose as a
function of depth (beyond 2 cm). It is important to point out that the difference in NTD2.0
between considering 8 mm or 12 mm of skull is about 15 Gy. As a consequence, one should
prescribe doses that are several Gy below the tissue tolerances to account for these variations.
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Figure 6. PVDR as a function of depth for two separations between microbeams. The dashed and
solid curves correspond to c-t-c separations of 400 and 200 μm, respectively.
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Figure 7. Valley dose distribution as a function of depth for two separations between the
microbeams. The dashed and solid curves correspond to c-t-c separations of 400 and 200 μm,
respectively. The prescribed peak dose in the centre of the tumour, situated at a depth of 7.2 cm,
is 55 Gy in one fraction.
3.4. Dose distributions as a function of the separation between microbeams
Figure 6 compares the PVDR values for two c-t-c distances between microbeams, namely 200
and 400 μm. The PVDR for a c-t-c distance of 200 μm is lower because of the higher valley
dose. Figure 7 presents the valley dose distribution corresponding to a peak dose prescription
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of 55 Gy in the centre of the tumour. With a 200 μm c-t-c distance, it is possible to deliver a
maximum dose of only 27 Gy in the tumour, maintaining the healthy tissue under tolerances,
i.e. half than that for a c-t-c separation of 400 μm. The valley dose in a centrally located
tumour is now 3.3 Gy. Therefore, to scale up the doses with respect to the ones in conventional
radiosurgery, a c-t-c distance of 400 μm is recommended.
4. Conclusions
MC simulations in a human head phantom have been performed to define safe irradiation
protocols for the forthcoming clinical trials in MRT. The aim of these trials is the quest
for a radical treatment of gliomas, which are the most aggressive and radioresistant brain
tumours. The results of this work show that it is possible to deliver a relatively large dose to
the tumour and, at the same time, keep the valley dose in the healthy tissue under tolerances.
In order to establish the equivalence of the valley dose (one fraction) with the standard
fractionation scheme, the NTD2.0 has been used. The maximum peak dose that can be
prescribed to the tumour while sparing the surrounding normal tissue has been evaluated for
various tumour positions. The skull is the organ with the largest absorbed doses. For the
most conservative tumour location, i.e. in the centre of the brain, the maximum peak and
valley doses accomplishable in the tumour are 55 Gy and 2.6 Gy, respectively, in one fraction
and with a unidirectional irradiation. In this way, the valley dose in the healthy tissue will
remain under tolerances (5% probability of complication within 5 years). A level of 50%
probability of bone necrosis would be reached if the tumour were irradiated with a peak dose
of 62 Gy. Although there is no data on the doses required to ablate glioma tumours in humans
using MRT, existing data from conventional radiotherapy indicate that an aggressive treatment
would enhance the patient lifespan.
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